Published 2 days ago • loading... • Updated 2 days ago
[Opinion] Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (Clesrovimab) to Include Children up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease through Their Second RSV Season
Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending the approval of an expanded indication for ENFLONSIA® (clesrovimab) to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in children up to 24 months of age. [Merck] Press Release
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.